Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Revenue

Chengdu Olymvax Biopharmaceuticals had revenue of 157.80M CNY in the quarter ending March 31, 2026, with 80.37% growth. This brings the company's revenue in the last twelve months to 774.47M, up 27.90% year-over-year. In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M with 19.58% growth.

• Revenue (ttm): 774.47M
• Revenue Growth: +27.90%
• P/S Ratio: 18.36
• Revenue / Employee: 1.72M
• Employees: 451
• Market Cap: 14.22B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	704.16M	115.30M	19.58%
Dec 31, 2024	588.86M	92.74M	18.69%
Dec 31, 2023	496.12M	-51.36M	-9.38%
Dec 31, 2022	547.48M	60.33M	12.38%
Dec 31, 2021	487.15M	167.04M	52.18%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 6, 2026

Data Sources Report a data error